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Abstract
Bacillus Calmette-Guérin (BCG) vaccine is given to newborns soon after birth. BCG vaccine
overdose has been rarely reported. Here we report the outcome of newborns who accidently
received high dose BCG at a tertiary care hospital, Karachi. We reviewed records of 26 newborns, who accidentally received intradermal high dose BCG, used for the treatment of urinary bladder cancers and 80 times higher dose than the BCG used for routine vaccination.
The incident happened from 14-16th April, 2016 at Aga Khan University Hospital, Karachi.
Analysis was carried out using SPSS. A total of 23/26(88.5%) newborns were followed for
atleast 3 months and 11/26 (42.3%) were followed for atleast one year. 13/26 (50%) were
male. All 26 patients were prescribed isoniazid and rifampicin for 3 months. 3/26 (11.5%)
were lost to follow-up before completion of anti-tuberculous drugs (ATT). Lesions at the
BCG site were observed in 16/26 (61.5%) infants, of which 15 (93.8%) had a papule, 3
(18.8%) developed a pustule, 3 (18.8%) had skin induration and 2 (12.5%) had skin erythema. Axillary lymphadenopathy was observed in 1/26 (3.8%) patient. Coagulation was
deranged in 3/26 (11.5%) of babies. Intracranial bleeding was observed in 1/26 (3.8%)
case. Localized skin lesions were the most common adverse events. None of them developed clinical tuberculosis. Chemoprophylaxis for inadvertent high dose BCG administration
should be given for atleast 3 months. Furthermore, vigilant follow-up, transparency and disclosure are the vital steps in the management of any medical error.

Introduction
Bacillus Calmette-Guérin (BCG) vaccine, containing live attenuated strain of Mycobacterium
bovis, is given routinely to newborns as part of the Expanded Program on Immunization in
countries with high prevalence of TB. In Pakistan, BCG is given at birth to prevent infection
with Mycobacterium tuberculosis (TB) and is effective against severe infant tuberculous meningitis and miliary TB [1]. BCG is a safe vaccine but being live attenuated, there is a risk of localized inflammatory reactions (skin erythema, papule, pustule) and axillary lymphadenopathy
[2]. Vaccination is followed by development of a papule at injection site within 2–3 weeks of
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vaccination [3]. There are no universal criterions for defining a BCG adverse reaction. O’Brien
et al. have described local swelling, regional lymph node enlargement >20mm, ulcer for
greater than 6 weeks as mild complications, ‘axillary abscess or fistula as moderate complications and disseminated BCG infection as severe [4, 5].
Overdose with BCG is rarely reported; with estimated incidence of 2.2 cases per 1 million
doses distributed, a likely underrepresentation due to either underutilization of vaccine doses
distributed or underreporting of medical errors [6, 7]. There is recent increased use of BCG
intravesically at higher doses for immunotherapy management of early-stage bladder cancer
[8]. If this is wrongly injected as neonatal BCG, an overdose can occur. It can also occur if an
excessive volume is injected or BCG vaccine reconstituted with the inappropriate volumes of
diluent [6].
A European report by Lotte et al. in 1984 documented most side effects of BCG overdose
following immunization were exaggerated local reactions of large, deep ulcers, necrotic lesions
or abscesses, and sometimes regional suppurative lymphadenitis were observed and only 8%
developed systemic complications including fever, headache, and malaise [9, 10]. In 1996, 857
infants being injected intradermally with a percutaneous BCG preparation in Manchester
which was 5 times the upper limit of the normal dose, 61 (11%) of these infants had adverse
local reactions and 48 infants (8.6%) had axillary lymphadenopathy. None of the infant developed disseminated TB [4]. Such accident also reported from Taiwan in 2012 in which the vial
was diluted with 2mL instead of 3mL. That vaccine was then administered to 20 healthy
infants. 3 (15%) of these infants developed injection site abscesses that resolved within 6 weeks
[4]. There have been multiple case reports on BCG overdose in which the authors reported
localized reactions only [4, 6, 9].
There is no consensus and large variations in treatment of BCG overdose. Management
options have included surgical excision within 12 hours of administration, use of anti-tuberculosis medications, or aspiration of formed abscesses [6]. It is also suggested to follow-up posttherapy to check for any reactivation of local or regional lesions [4]. Here we are reporting the
outcome of 26 healthy newborns who were accidentally vaccinated with BCG usually given in
patients with bladder cell carcinoma intravesically.

Material and methods
Description of the incident
At the Aga Khan University Hospital, 26 newborns born between 11th-14th April, 2016 were
accidentally vaccinated from 14th-16th April, 2016 with 0.05 ml of ONCO-BCG which is used
for intravesical instillation in patients with bladder cell carcinoma. The dose given was equivalent to 20 mg, which was 80 times higher than the dose of routine BCG vaccine given at birth.
The ONCO-BCG contains a live lyophilized preparation derived from attenuated strain of
Mycobacterium bovis. The incident was unconditionally disclosed to the parents as soon as
the error was noted. All the newborns were examined and the ones who were already discharged were called back to clinic the next day and examined. These parents were provided
with an emergency contact number of a Nurse Manager who could be reached 24/7 for any
concerns. The incident was also informed to the pediatricians and gynecologists responsible
for the babies. Furthermore, a panel was arranged consisting of pediatric infectious disease
specialists, nursing supervisors, pharmacist, departmental chair and hospital ethics committee.
Our team also contacted international experts who have dealt with the similar situation on
how to best treat and follow up with these patients. There was lack of a prior experience on the
management of such events; therefore, a consensus was taken to initiate post-exposure prophylaxis with 10mg/kg/day of isoniazid and 15mg/kg/day of rifampicin for at least 3 months.
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A stringent protocol of follow-up was planned with an infectious disease specialist. All the
babies were followed in Infectious disease clinics at monthly intervals or in between if needed.
The cost of the treatment was borne by the hospital for a period of one year.

Data collection
Records of 26 newborns who had received BCG overdose accidentally from 14th -16th April,
2016 were reviewed retrospectively. Data on local and systemic adverse events such as skin
changes including skin erythema, induration, pustules, vesicles, ulcers or abscess formation,
osteomyelitis, humeral osteitis, lymphadenitis, pallor, jaundice, intracranial bleeding or disseminated TB, number of follow-up visits and outcome of the newborns was extracted from
the medical record files. Statistical analysis was carried out by using SPSS version 17. Frequencies and percentages were reported for categorical variables like gender, ward unit, ATT
received, and adverse effects. Means and standard deviations (medians and IQR where appropriate) were reported for age at vaccination, gestational age, duration of ATT, follow-up days
and number of clinic visits.

Results
The median (min- max) age of newborns at vaccination was 2.0 (2.0–4.0) days. 13/26 (50%)
were male and 24/26 (92%) were born at full term of gestation. Out of 26 babies 23(88.5%)
were followed for at least 3 months and almost half, 11/26 (42.3%) were followed for one year.
All 26 patients were prescribed two drugs (isoniazid and rifampicin) anti-tuberculous treatment (ATT) for 3 months. Only 3/26 (11.5%) were lost to follow-up before completion of
ATT. However, we have contacted these 3 families on phone; all babies have completed their
ATT course and are doing well (Table 1). 3/26(11.5%) babies received ATT for more than 3
months. Localized skin lesions were observed in 16/26 (64%) of newborns. Majority of the
localized skin lesions resolved in the first two weeks of life. One newborn developed a persistent weeping skin lesion at the left big toe and underwent skin biopsy at 3 months of age that
showed inflammatory changes with eosinophilia. The lesion resolved in 3 months with antiallergy, topical steroids and antibiotics. Coagulation was deranged in 3/26 (11.5%) babies. Out
Table 1. Demographics of newborns who had received high dose BCG vaccine.
Variables

n/N (%)

Age at vaccination (days),Median(Min-Max)

2.0 (2.0–4.0)

Gestational Age(weeks), Mean ± SD

38±1.2

Gender
Male

13/26 (50)

Ward unit
A2 well baby nursery

14/26 (53.8)

B2 well baby nursery

11/26 (42.3)

Community Health Center

1/26 (3.8)

Length of hospital stay (days), Mean ±SD

3.6±1.7

Adverse reaction developed

22/26 (84.6)

a

26/26 (100)

Duration of aATT(days), Median (IQR)

90 (30)

Follow-up(days),Mean ±SD

252 ± 233

No. of clinic visits, Median (IQR)

10 (7)

ATT received

a

ATT: Anti-tuberculosis treatment

https://doi.org/10.1371/journal.pone.0219324.t001
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of three babies, 2 presented with post circumcision bleed, intracranial bleeding was observed
in 1/26 (3.8%) babies at 37Th day of life when he was admitted with complaints of fever, cough
and irritability. During the hospital stay he developed right sided focal seizure. His laboratory
investigations revealed hypocalcaemia (serum calcium: 6.5mg/dl), sudden drop in hemoglobin
(Hb 6.3 g/dl), had a normal coagulation profile (INR of 1.2), a normal platelet count (427� 109/
L) and also received vitamin k at birth. Neuroimaging had done which was suggestive of left
subdural hematoma and minimal subarachnoid hemorrhage. Considering normal coagulation
profile factor XIII deficiency was also ruled out (Factor XIII: 102% (Normal: 70%-140%). He
was managed conservatively with calcium supplementation, vitamin K, antiepileptic, antibiotics and packed cell transfusion. He was discharged in stable condition and remained well on
antiepileptic with no focal neurologic deficit. After a period of one year, neuroimaging showed
resolution of hemorrhage. However, he achieved his developmental milestones late according
to his age. None of the patients developed fever, osteomyelitis and clinical or disseminated TB.
(Tables 2 and 3)

Discussion
In our study, 22/26 patients had at least one symptom following high dose BCG administration. Most of the patients (57.7%) developed a papule. 11.5% developed a pustule, 7.7%
developed skin erythema, and 3.8% developed axillary lymphadenopathy. 1/26 children also
developed jaundice, but he was lost-to-follow-up. None of the patients developed fever disseminated TB or osteomyelitis. These findings are in consistent with the literature in which
the most common symptoms following a high dose BCG vaccine were adverse local events
and few systemic complications [10]. A European report by Lotte et al. in 1984 documented
most side effects of BCG overdose following immunization were exaggerated local reactions
cases of large, deep ulcers, necrotic lesions or abscesses, and sometimes regional suppurative
lymphadenitis were observed and only 8% developed systemic complications including
fever, headache, and malaise [9, 10]. A study published in 1996 in Manchester, documented
857 cases of infants between July and November 1994 being injected intradermally with a
percutaneous BCG preparation which was 5 times the upper limit of the normal dose. 61
(11%) of these infants had adverse local reactions. 48 infants (8.6%) had axillary lymphadenopathy, 6 infants had papules >10 mm, and 6 of the infants had ulcer >10 mm. One infant
Table 2. Adverse reactions of BCG overdose in newborns at a tertiary care hospital, Karachi.
Variables

n/N (%)

Localized skin lesions at aBCG site

16/26 (61.5)

Erythema

2/16 (12.5)

Induration

3/16 (18.8)

Papule

15/16 (93.7)

Pustule

3/16 (18.7)

Jaundice

1 (3.8)

Lymphadenopathy
Axillary

1 (3.8)

Intracranial bleeding

1 (3.8)

Outcome
Follow-up completed for one year

11/26 (42.3)

Survived

11/11 (100)

a

BCG: Bacillus Calmette-Guérin

https://doi.org/10.1371/journal.pone.0219324.t002

PLOS ONE | https://doi.org/10.1371/journal.pone.0219324 July 10, 2019

4 / 10

Outcome of inadvertent high dose BCG administration in newborns at a tertiary care hospital, Karachi

Table 3. Clinical profile and laboratory characteristics of newborns received high dose BCG vaccine in a tertiary care hospital, Karachi.
S.
No

Weight
(kg)

ATT
duration
(Days)

Adverse Reaction

Day of life
(At which
adverse event
developed)

Day of life (DOL) at which test
performed/Laboratory
abnormalities

Time to resolution of
adverse event (days)

No. of
follow up
visits

Last
followup day

Outcome

1.

2.3

97

1.5 cm papule

2

None

Not documented

8

132

No
systemic
disease

2.

3.1

29

Jaundice

29

29th DOL/

Lost to follow up

1

29

Lost to
follow up

No
systemic
disease

Survived
Total bilirubin: 8.7 mg/dl
Direct bilirubin:0.9 mg/dl
3.

3.4

134

1.0 cm papule

6

None

Not documented

12

146

4.

3.6

90

1.5 cm papule

6

None

Not documented

14

212

5.

3.8

90

1.0 cm papule

5

None

Not documented

3

46

Lost to
follow-up

6.

2.7

85

1.0 cm papule

5

None

Not documented

9

149

No
systemic
disease

7.

3.0

90

0.5 cm papule

7

None

Not documented

10

252

8.

3.1

90

Skin erythema

4

None

Not documented

20

676

1.0 cm pustule

8

9.

3.6

105

1.0 cm papule

6

None

Not documented

7

301

10.

2.4

81

1.0 cm papule

6

None

Not documented

7

102

11.

3.0

85

None

NA

None

NA

12

257

12.

3.0

60

1.0 cm papule

6

None

60

12

494

13.

3.0

81

1.0 cm papule

5

None

Not documented

22

327

Survived
No
systemic
disease
Survived

Survived
No
systemic
disease
Survived
No
systemic
disease
Survived
No
systemic
disease
Survived
No
systemic
disease
Survived
No
systemic
disease
Survived
No
systemic
disease
Survived
No
systemic
disease
Survived
(Continued )
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Table 3. (Continued)
S.
No

Weight
(kg)

ATT
duration
(Days)

Adverse Reaction

Day of life
(At which
adverse event
developed)

Day of life (DOL) at which test
performed/Laboratory
abnormalities

Time to resolution of
adverse event (days)

No. of
follow up
visits

Last
followup day

Outcome

14.

2.9

90

None

NA

None

NA

6

252

No
systemic
disease

15.

3.8

90

Skin erythema and
induration

12

None

1

10

249

16.

3.2

90

Post circumcision
bleed with deranged
coagulation

32

37ThDOL/

1 day after receiving
vitamin K therapy

12

385

Survived
No
systemic
disease
Survived

a

PT: 42.7 seconds

No
systemic
disease
Survived

a

INR: 4.3 ratio

a

APTT:70.8 seconds

Factor X: 10% (Normal: 70%152%)
17.

3.1

90

Skin pustule

2

None

2

Intracranial Bleed

37

38th DOL

355 (MRI brain
performed showed
resolution of
hemorrhage)

CT Brain (Left subdural
hemorrhage approximately 5.0 mm
in thickness with significant mass
effect and minimal subarachnoid
hemorrhage in the left temporal
lobe)

5

699

No
systemic
disease

Hb: 8.3 g/dL
Platelet: 427� 109/L
a

PT: 12.6 seconds

Survived

a

INR: 1.2 ratio

a

APTT:29.1 seconds

VWF: 262% (Normal: 50%-160%)
Factor XIII: 102%(Normal: 70%140%)
18.

3.0

90

1.0 cm papule

6

Deranged coagulation

42

None

27

42nd DOL

APTT:47 seconds

9 days after receiving
vitamin K therapy
(Coagulation profile
was not checked in
between)

None

Not documented

a

PT: 17 seconds
a

INR:1.7 ratio

a

19.

20.

3.0

2.9

90

60

• cm papule

8

Unilateral axillary
Lymphadenopathy (9.0
mm)

8

None

NA

17

487

Survived

11

342

Not documented

None

NA

No
systemic
disease

No
systemic
disease
Survived

13

622

No
systemic
disease
Survived
(Continued )
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Table 3. (Continued)
S.
No

Weight
(kg)

ATT
duration
(Days)

Adverse Reaction

Day of life
(At which
adverse event
developed)

Day of life (DOL) at which test
performed/Laboratory
abnormalities

Time to resolution of
adverse event (days)

No. of
follow up
visits

Last
followup day

Outcome

21.

3.3

90

1.0 cm papule

7

None

Not documented

8

232

No
systemic
disease

22.

3.3

90

1. cm pustule

5

None

13

35

781

Persistent weeping skin
lesion on left big Toe

77

90th DOL/Skin punch biopsy
(inflammatory changes with
eosinophilia)

90

Post circumcision
bleed with deranged
coagulation

36

36th DOL

2 days after receiving
vitamin k therapy

Survived

a

PT 123 seconds

No
systemic
disease
Survived

a

INR 12.9 ratio

a

APTT 140.6 seconds

Factor VII = 3% (67%-143%)
Factor IX = 10%(70%-152%)
Factor X = 2%(50%-163%)
23.

3.6

90

1.0 cm induration

7

None

16

6

205

No
systemic
disease
Survived

24.

3.0

90

2.0 cm papule

7

None

Not documented

14

583

No
systemic
disease
Survived

25.

3.2

57

1.0 cm papule

10

None

1

14

663

No
systemic
disease
Survived

26.

3.5

14

1.0 cm induration

14

None

Lost to follow-up

1

14

Lost to
follow-up

a

PT: Prothrombin Time, APTT: Activated Partial Thromboplastin Time, INR: International Normalised Ratio

https://doi.org/10.1371/journal.pone.0219324.t003

had an abscess which was aspirated by a needle. One infant presented at 4 months with
severe combined immune deficiency (Omenn syndrome) but she did not have disseminated
BCG infection [4].In the present study, it was observed that majority of the superficial local
skin reactions occurred in the first 2 weeks of life which can also be seen normally with a
routine BCG vaccination after birth. Almost all routine vaccine recipients experience an
injection site reaction characterized by a papule which commences 2 or more weeks after
immunization and then may progress to become ulcerated healing after 2–5 months leaving
a superficial scar [11].However, severe local abscess and keloid formation or lymphadenitis
following BCG vaccination are rarely reported and are only limited to few case reports [11].
Wei et al. conducted a study in Taiwan about an event that occurred in 2012 in which the
vial was diluted with 2mL instead of 3mL. That vaccine was then administered to 20 healthy
infants. 3 (15%) of these infants developed injection site abscesses that resolved within 6
weeks. They all recovered without significant complications in the 18 month follow up
period [12]. A case report on a 13-year-old boy who mistakenly received intramuscular
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(IM) intravesical BCG reported that he suffered from fever, anemia, pancytopenia, enlarged
spleen, hydronephrosis and fluid around the liver. However, a relationship was not established between the symptoms and IM intravesical BCG administration. At 2 months, he
developed cellulitis and swollen lymph nodes were present on sonography. The skin biopsy
showed poorly formed granulomas and he was treated with isoniazid, ethambutol, and
rifampicin for 6 months [13]. In a 60-year-old man 4 vials of intravesical BCG were administered intramuscularly which caused fever, headache, and sweating. He then developed
local indurations and hypogastric pain after 3 days and received prophylactic isoniazid and
rifampicin course [14]. The babies were followed up to a mean follow-up time of 252 days
which corresponds to around 8.4 months. The median duration of ATT given was 90 days.
There is no consensus on how to best manage patients with BCG overdose. Puliyel et al. in
1996 mainly managed patients by observation except for 1 patient who received abscess
aspiration and 1 patient with Omenn syndrome who received ATT after diagnosis [4].
Miles and Shaw in 1996 also managed patients using observation. In the study by Ashraf,
isoniazid and rifampicin were given for 2 months, another case study by Ritz et al. a surgical
excision of the lump was done and then was treated with Isoniazid and Rifampicin for 6
weeks [6, 15], whereas Wei et al. in their study managed the children by only observing and
following them [12].
There was one patient who suffered an intracranial bleed. This baby had a normal coagulation profile (INR of 1.2), a normal platelet count (427� 109/L) and also received vitamin k at
birth. 3/26 (11.5%) patients had an INR of >1.0. Two of them had a post circumcision bleed.
One had factor X deficiency and another kid had factor VII, IX and X deficiency which are
vitamin K dependent factors. These babies responded to vitamin K therapy. This might be
because of rifampicin induced coagulopathy due to vitamin K deficiency. Anti-tuberculosis
medication can induce thrombocytopenia and coagulopathy which is mostly due to rifampicin
[16, 17]. The pathogenesis of rifampicin-induced vitamin K deficiency is most likely to be multifactorial. It can be because of impairment of vitamin K production from gut flora due to
intestinal decontamination or may be due to oxidative degradation of vitamin K as a result of
hepatic microsomal enzyme stimulation [18]. Chen et al. reported rifampicin induced disseminated intravascular coagulation (DIC) in a 22 year old boy treated for pulmonary Tuberculosis
at the West China Hospital [17]. Sampaziotis et al. also revealed rifampicin induced severe coagulopathy in patients with primary sclerosing cholangitis and refractory pruritus [18]. Kang
et al. observed a case of a 68-year-old woman developing an acute subdural hemorrhage secondary to rifampicin induced thrombocytopenia [19]. According to the literature, rifampicininduced thrombocytopenia usually occurs in high dose intermittent treatment because neutralizing antibodies form during continuous daily treatment [19]. It is important to start treatment early in cases of drug-induced thrombocytopenia to prevent morbidity and mortality
[16]. In our study we observed coagulopathy however none of the newborns experienced
thrombocytopenia. This could suggest that maybe instead of using both rifampicin and isoniazid as chemoprophylaxis; we can use only isoniazid to decrease the chance of thrombocytopenia, coagulopathy and bleeding. However, considering the nature of study and small sample
size we can’t establish its temporality and causation.
There is very little data on BCG vaccination overdose in Pakistan. Moreover, medical errors
tend to be underreported. By reporting these medical errors and following-up on the patients
we can better understand the consequences of the medical error and their management. It also
emphasizes on having checks to prevent medical errors like this in the future by increasing the
awareness of health care staff. Small sample size and single centered retrospective nature are
the major limitations of our study.
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Conclusion
We conclude that local adverse reactions are more common with accidental administration of
high dose BCG vaccine. We recommend chemoprophylaxis for such incidents. Furthermore,
vigilant follow-up, transparency and disclosure are the vital steps in the management of any
medical error.
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